Bradley A. McGregor

7.2k total citations · 2 hit papers
176 papers, 3.2k citations indexed

About

Bradley A. McGregor is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Bradley A. McGregor has authored 176 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pulmonary and Respiratory Medicine, 87 papers in Oncology and 72 papers in Surgery. Recurrent topics in Bradley A. McGregor's work include Renal cell carcinoma treatment (82 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Bladder and Urothelial Cancer Treatments (62 papers). Bradley A. McGregor is often cited by papers focused on Renal cell carcinoma treatment (82 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Bladder and Urothelial Cancer Treatments (62 papers). Bradley A. McGregor collaborates with scholars based in United States, Canada and France. Bradley A. McGregor's co-authors include Toni K. Choueiri, Guru Sonpavde, Aly‐Khan A. Lalani, Lauren C. Harshman, Jonathan E. Rosenberg, Arjun Vasant Balar, Daniel P. Petrylak, Elisabeth I. Heath, Peter H. O’Donnell and Evan Y. Yu and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bradley A. McGregor

157 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2019 435 citations Bradley A. McGregor, Elisabeth I. Heath et al. Journal of Clinical Oncology profile →
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 175 citations Jae‐Lyun Lee, Yohann Loriot et al. profile →

Peers

Countries citing papers authored by Bradley A. McGregor

Since Specialization

Citations

This map shows the geographic impact of Bradley A. McGregor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley A. McGregor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley A. McGregor more than expected).

Fields of papers citing papers by Bradley A. McGregor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley A. McGregor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley A. McGregor. The network helps show where Bradley A. McGregor may publish in the future.

Co-authorship network of co-authors of Bradley A. McGregor

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley A. McGregor. A scholar is included among the top collaborators of Bradley A. McGregor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley A. McGregor. Bradley A. McGregor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. 2025 ·Journal of Clinical Oncology ·Toni K. Choueiri, Jae‐Lyun Lee, Jaime R. Merchan, Amita Patnaik, (unknown), Alexandra Drakaki, Moshe Chaim Ornstein, Bradley A. McGregor, Ralph J. Hauke, (unknown), Brian I. Rini, Pedro C. Barata, Paul Foster, Sutapa Mukhopadhyay, (unknown), (unknown), Manish Monga, Dimitry S.A. Nuyten, Sun Young Rha	0
2	Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer 2024 ·European Urology Oncology ·Praful Ravi, (unknown), Wanling Xie, (unknown), (unknown), (unknown), Himisha Beltran, Kerry L. Kilbridge, Martin T. King, Bradley A. McGregor, Alicia K. Morgans, Mark M. Pomerantz, Mary‐Ellen Taplin, Alok K. Tewari, Srinivas R. Viswanathan, Xiao X. Wei, Mai Anh Huynh, Atish D. Choudhury	1
3	Characterization of FOLH1 Expression in Renal Cell Carcinoma 2024 ·Cancers ·(unknown), Elizabeth Pan, (unknown), Andrew Elliott, Shankar Siva, Praful Ravi, Bradley A. McGregor, Aditya Bagrodia, Ithaar Derweesh, Pedro C. Barata, Elisabeth I. Heath, Emmanuel S. Antonarakis, Sourat Darabi, Dave S.�B. Hoon, Amir Mortazavi, (unknown), Chadi Nabhan, Shuanzeng Wei, Rana R. McKay	1
4	CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2024 ·Journal of Clinical Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Nobuaki Matsubara, Stéphane Oudard, Fred Saad, Axel S. Merseburger, Andrey Soares, Bradley A. McGregor, Bogdan Żurawski, Scott North, Marinos Tsiatas, Igor Bondarenko, (unknown), (unknown), Keerti Vardhan Sharma, (unknown), Roberta Ferraldeschi, Fong Wang, Sumanta K. Pal	20
5	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO). 2024 ·Journal of Clinical Oncology ·Bradley A. McGregor, Lucia Kwak, Guru Sonpavde, Stephanie Berg, Toni K. Choueiri, Joaquim Bellmunt, Charlene Mantia	2
6	Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer 2024 ·Journal for ImmunoTherapy of Cancer ·Praful Ravi, Dory Freeman, Jonathan Thomas, Arvind Ravi, Charlene Mantia, Bradley A. McGregor, Jacob E. Berchuck, (unknown), Petra Budde, Behnaz Ahangarian Abhari, (unknown), (unknown), (unknown), (unknown), (unknown), Hans‐Dieter Zucht, Guru Sonpavde	2
7	Clinical Outcomes of Patients with Oligometastatic Renal Cell Cancer Treated with Stereotactic Body Radiation Therapy: Results from a Prospective Registry Trial 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Yu‐Hui Chen, Pat Doyle, (unknown), (unknown), Theodore J. Perkins, David Kozono, Bradley A. McGregor, Wei Xu, Atish D. Choudhury, Tracy A. Balboni, Alexander Spektor, Mai Anh Huynh	0
8	1690O NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study 2024 ·Annals of Oncology ·Eric Jonasch, Bradley A. McGregor, Pavlos Msaouel, (unknown), Evan Hall, (unknown), Gerald S. Falchook, (unknown), Yousef Zakharia, (unknown), Michael S. Gordon, (unknown), Christopher W. Ryan, Ramaprasad Srinivasan, Jim Xiao, Weimin Sun, (unknown), (unknown), Joanne Lager, (unknown)	4
9	Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study 2024 ·The Lancet ·Toni K. Choueiri, Laurence Albigès, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina‐Cerrillo, Benjamin Garmezy, Pedro C. Barata, Arnab Basu, María T. Bourlon, Helen Moon, Raffaele Ratta, Rana R. McKay, Alex Chehrazi‐Raffle, Hans J. Hammers, Daniel Y.C. Heng, (unknown), Kathryn E. Beckermann, Bradley A. McGregor, Robert J. Motzer	32
10	1902P Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC) 2023 ·Annals of Oncology ·(unknown), Kosuke Takemura, Devon J. Boyne, Matthew T. Warkentin, Darren R. Brenner, (unknown), J. Connor Wells, Chris Labaki, Bradley A. McGregor, (unknown), Luís Meza, Sumanta K. Pal, Benoit Beuselinck, Rana R. McKay, Bernadett Szabados, Thomas Powles, Takeshi Yuasa, Leopold Ludwig, Toni K. Choueiri, (unknown)	2
11	The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma 2023 ·Annals of Oncology ·Bradley A. McGregor, Guru Sonpavde, Lucia Kwak, Meredith M. Regan, Xīn Gào, (unknown), Charlene Mantia, Xiao X. Wei, (unknown), Stephanie Berg, Praful Ravi, M. Dror Michaelson, Toni K. Choueiri, Joaquim Bellmunt	51
12	CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) 2022 ·Clinical Genitourinary Cancer ·Vishal Navani, J. Connor Wells, Devon J. Boyne, Winson Y. Cheung, Darren M. Brenner, Bradley A. McGregor, Chris Labaki, Andrew Schmidt, Rana R. McKay, Luís Meza, Sumanta K. Pal, Frede Donskov, Benoit Beuselinck, (unknown), Lisa Ludwig, Thomas Powles, Bernadett Szabados, Toni K. Choueiri, Daniel Y.C. Heng	12
13	Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma 2022 ·Clinical Genitourinary Cancer ·(unknown), (unknown), (unknown), Chinmay Jani, Tian Zhang, Nazlı Dizman, Luís Meza, (unknown), Chun Loo Gan, Pedro C. Barata, Mehmet Asım Bilen, Xin Gao, Daniel Y.C. Heng, Sumanta K. Pal, (unknown), Deepak Kilari, Marina D. Kaymakcalan, Bradley A. McGregor, Toni K. Choueiri, Rana R. McKay	2
14	A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer 2022 ·Future Oncology ·Neeraj Agarwal, Arun Azad, Joan Carles, Simon Chowdhury, Bradley A. McGregor, Axel S. Merseburger, Stéphane Oudard, Fred Saad, Andrey Soares, Fawzi Benzaghou, Yannick Kerloëguen, Akiko Kimura, Nehal Mohamed, Ashok Panneerselvam, Fong Wang, Sumanta K. Pal	26
15	1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study 2022 ·Annals of Oncology ·Camillo Porta, (unknown), Robert J. Motzer, (unknown), Tomáš Büchler, Naveen S. Basappa, (unknown), Sergei Tjulandin, S.H. Park, Bohuslav Melichar, Thomas E. Hutson, Carlos Alemany, Bradley A. McGregor, Cixin He, Rodolfo F. Perini, Kalgi Mody, Jodi A. McKenzie, Toni K. Choueiri	4
16	Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial 2021 ·Clinical Cancer Research ·Mehmet Asım Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albigès, Lance C. Pagliaro, Éric Voog, Elaine T. Lam, Nikolay Kislov, Bradley A. McGregor, Aly‐Khan A. Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B. Robbins, Toni K. Choueiri	28
17	PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) 2021 ·Value in Health ·Bradley A. McGregor, Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suárez, María T. Bourlon, (unknown), Ella X. Du, (unknown), (unknown), Keith A. Betts, (unknown), Toni K. Choueiri	2
18	Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis 2020 ·European Urology Open Science ·Karl H. Tully, Marieke J. Krimphove, (unknown), Maya Marchese, Adam S. Kibel, Joachim Noldus, Luis A. Kluth, Bradley A. McGregor, Steven L. Chang, (unknown), Matthew Mossanen	1
19	Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma 2020 ·European Urology Open Science ·J. Connor Wells, Shaan Dudani, Gan Chen, Igor Stukalin, Arun Azad, Elizabeth Liow, Frede Donskov, Takeshi Yuasa, Sumanta K. Pal, Gloria Velasco, Laura D. Wood, Aaron R. Hansen, Benoit Beuselinck, Christian Kollmannsberger, (unknown), Bradley A. McGregor, Mei Sheng Duh, Lynn Huynh, D.Y.C. Heng	1
20	709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study 2020 ·Annals of Oncology ·Bradley A. McGregor, Neeraj Agarwal, Cristina Suárez, (unknown), William K. Kelly, Lance C. Pagliaro, Ulka N. Vaishampayan, Daniel Castellano, Yohann Loriot, Scott Werneke, Desmond Curran, Toni K. Choueiri, Sumanta K. Pal	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact